The amino acid cysteine plays an indispensable role in cellular physiology, acting as a building block for proteins and serving as a critical agent in the protection of cells against oxidative damage. Traditionally, scientists have understood that cysteine cannot be directly absorbed from the extracellular environment; instead, cells rely on a system known as the disulfide reductase pathway to convert cystine—an oxidized dimeric form of cysteine—into usable cysteine. This process hinges on the activity of specific enzymes called disulfide reductases, which chemically cleave cystine’s disulfide bond to maintain cellular cysteine pools essential for survival and homeostasis.

For decades, this biochemical paradigm was considered inviolable. The assumption was that cells devoid of either disulfide reductase enzyme could not survive due to their inability to maintain intracellular cysteine concentrations. This dogma was first seriously challenged in 2014 when Dr. Ed Schmidt, a geneticist specializing in molecular biology at Montana State University, observed an anomalous phenotype in genetically engineered mice. These mice, designed to lack either of the two primary disulfide reductases in their liver cells, nonetheless survived, contradicting the established scientific consensus that their survival was biochemically implausible.

Dr. Schmidt and his research team embarked on a multi-year investigation to decipher the molecular basis behind this unexpected resilience. Partnering with collaborators from the Hungarian National Institute of Oncology, who contributed advanced analytical instrumentation, the team gradually elucidated a secondary biochemical pathway that compensates for the loss of classical disulfide reductase activity. This backup mechanism chemically targets and severs a carbon-sulfur (C–S) bond adjacent to the cystine molecule’s disulfide linkage. The cleavage process releases free cysteine, ensuring a continuous supply despite the absence of canonical enzymatic reductases.

This discovery not only redefines fundamental concepts in cellular metabolism but also hints at an evolutionary adaptive strategy. It suggests that ancestral multicellular organisms may have developed this alternate cysteine biosynthesis route to survive in environments laden with electrophilic toxins—reactive organic compounds that organisms produce to deter predators or competitors. The newfound backup system could have endowed early life forms with robust cellular defenses capable of neutralizing these harmful molecules, thereby promoting survival under toxic stress conditions.

Crucially, the implications of this biological redundancy extend into the realm of cancer biology. Many malignancies are characterized by elevated oxidative stress and a heightened need for antioxidant defenses, such as those mediated by cysteine. Dr. Schmidt posits that this secondary cysteine-producing pathway may inadvertently empower certain cancer cells to resist conventional treatments like chemotherapy, radiation, and emerging immunotherapies. Tumor cells exploiting this hidden metabolic circuit could maintain their cysteine reservoirs under chemotherapeutic assault, contributing to treatment resistance and relapse.

Understanding the molecular details of this alternative cysteine synthesis pathway thus opens the possibility of developing targeted inhibitors that selectively disrupt this backup system in cancer cells. By doing so, researchers aim to sensitize tumors to existing therapies, enhancing their efficacy and potentially reducing required dosages, thereby mitigating treatment-related toxicity. The strategic manipulation of metabolic vulnerabilities stands as a promising frontier in precision oncology, offering hope for more effective cancer management.

The journey toward this breakthrough encompassed nearly a decade of meticulous experimentation. After genetically abolishing the canonical disulfide reductases in murine models, Dr. Schmidt’s group employed a combination of gene expression analysis, biochemical assays, and metabolite profiling to reveal the enzymatic and chemical underpinnings of the alternative pathway. Undergraduate students who contributed as co-authors gained invaluable hands-on experience in advanced genetic manipulation and analytical biochemistry, embodying the collaborative spirit of modern scientific research.

Dr. Schmidt’s work, conducted within the Department of Microbiology and Cell Biology at Montana State University’s College of Agriculture, exemplifies how fundamental research into molecular and cellular processes can yield insights with far-reaching translational potential. The research was further bolstered by the integration of multidisciplinary expertise, combining genetics, enzymology, and oncology, which was pivotal in uncovering the nuanced interactions underlying cysteine biosynthesis.

Moreover, this discovery underscores the dynamic plasticity of cellular metabolism and highlights how cells possess enigmatic strategies to maintain homeostasis under genetic or environmental duress. It challenges the notion of metabolic inflexibility and suggests that cellular biochemistry is wired for resilience, equipped with backup systems that are only revealed under specific stress conditions or genetic perturbations.

Looking ahead, the team aims to explore the prevalence and regulation of this backup cysteine synthesis mechanism in human tissues and cancer models. Deciphering whether certain cancer types rely disproportionately on this pathway could inform the design of novel therapeutic interventions that selectively target tumor cell metabolism without compromising normal cells.

Such a paradigm-shifting advancement in our understanding of amino acid metabolism not only redefines textbook biology but also provides a platform for innovative approaches to combat diseases characterized by oxidative stress and metabolic maladaptation, particularly cancer. As this exciting field of research unfolds, it promises to deepen our comprehension of cellular survival strategies and offer tangible benefits for human health.

Subject of Research: Cellular metabolism and cysteine biosynthesis under disulfide reductase deficiency in mammalian cells

Article Title: Cystine C–S bond cleavage fuels cysteine production under disulfide reductase deficiency

News Publication Date: 21-May-2026

Web References: https://www.nature.com/articles/s41589-026-02213-1?utm_medium=organic_social&utm_source=partner&utm_content=null&utm_term=null&utm_campaign=CONR_JRNLS_LYLT_GL_PJNL_06PJ3_ARTPROMTK

Keywords: cysteine, cystine, disulfide reductase, amino acid biosynthesis, cellular metabolism, molecular genetics, cancer therapy, oxidative stress, metabolic pathways, enzymology, cellular resilience, biochemical adaptation

Angiogenesis, the formation of new blood vessels from pre-existing vasculature, plays a critical role in normal physiological processes such as wound healing and embryonic development. However, aberrant or pathological angiogenesis contributes to a spectrum of diseases, including tumor growth where excess blood vessel formation facilitates nutrient supply to malignant cells, thus fueling aggressive disease progression. Targeting angiogenesis has therefore become a central focus of contemporary biomedical research, aiming to halt disease advance by interrupting vascular supply lines.

The study’s focus on FRZB, a secreted frizzled-related protein known primarily for its involvement in Wnt signaling, unravels an unexpected function beyond its canonical roles. Researchers discovered that FRZB impedes angiogenic processes through an intricate regulatory axis involving Caveolin-1 (Cav-1) and Transforming Growth Factor-beta (TGFβ). This finding delineates a critical checkpoint in vascular regulation that had previously escaped comprehensive mechanistic exploration.

Caveolin-1, an integral membrane protein and principal component of caveolae structures, has been recognized for its multifaceted role in signal transduction, lipid regulation, and endocytosis. In vessel biology, Cav-1 modulates endothelial function and vascular tone. The interplay between FRZB and Cav-1 as characterized by Chen et al. introduces a paradigm wherein FRZB enhances Cav-1 stability and function, thus curbing aberrant angiogenic signaling.

At the heart of this mechanism lies TGFβ signaling, a quintessential pathway implicated in vascular homeostasis, cellular proliferation, and differentiation. While TGFβ possesses dualistic properties that can promote or inhibit angiogenesis depending on cellular context and receptor interaction, the research delineates how FRZB-induced modulation of Cav-1 effectively biases this signaling axis toward anti-angiogenic outcomes. By orchestrating Smad-dependent pathways, FRZB-Cav-1 cooperation mitigates endothelial proliferation and migration, thereby suppressing neovascularization.

Methodologically, the investigative team employed a combination of in vitro endothelial cell cultures, advanced imaging techniques, and in vivo angiogenesis models including murine retinal vasculature and tumor xenografts. Quantitative assays measuring capillary tube formation and endothelial migration corroborated the suppressive effects of FRZB on angiogenic competence. The use of Cav-1 knockout models affirmed the essential role of this scaffold protein in mediating FRZB’s functional effects.

On a molecular level, biochemical analyses unveiled that FRZB enhances Caveolin-1 expression and reduces its ubiquitination-mediated degradation. This stabilization increases the available Cav-1 pool within caveolae domains, facilitating recruitment and activation of TGFβ receptors under a repressive configuration unfavorable for pro-angiogenic signaling cascades. Smad2/3 phosphorylation was selectively promoted in this context, steering downstream transcriptional programs that limit endothelial cell cycle progression.

The implications of these findings are vast. In cancer biology, inhibiting tumor angiogenesis remains a viable avenue to starve tumors of growth-supporting vasculature. FRZB’s capacity to quell angiogenesis via Cav-1 and TGFβ provides a targeted molecular lever potentially exploitable for anti-cancer therapeutics. Moreover, FRZB or Cav-1 mimetics could represent next-generation biologics with increased specificity and minimal off-target effects compared to conventional anti-angiogenic drugs such as VEGF inhibitors.

Beyond oncology, pathological neovascularization underlies complications in diabetic retinopathy and age-related macular degeneration, where excessive capillary growth results in vision-threatening retinal edema and hemorrhage. By dissecting the FRZB-Cav-1-TGFβ axis, the current study opens avenues for therapeutics that more prudently modulate vascular overgrowth in these chronic conditions, potentially extending patient quality of life.

Equally compelling is the contribution of this work to fundamental vascular biology. The confluence of extracellular signaling modulators like FRZB with membrane scaffolding proteins such as Cav-1 represents a sophisticated layer of regulation previously underappreciated. This cross-talk exemplifies how cells integrate extracellular cues to modulate intracellular signaling dynamics finely, adjusting physiological outcomes in a tissue-specific manner.

Future directions prompted by this study might include the development of FRZB-derived peptides or small molecules capable of mimicking its anti-angiogenic activity. Additionally, further elucidation of tissue-specific variations in Cav-1 expression and TGFβ responsiveness could refine therapeutic targeting to maximize efficacy while minimizing systemic side effects. The interplay between Wnt signaling pathways and TGFβ modulation mediated by FRZB also warrants deeper exploration to unravel potential synergistic or antagonistic roles in vascular pathophysiology.

In conclusion, Chen CJ and colleagues have charted a sophisticated and clinically relevant signaling axis whereby FRZB harnesses Caveolin-1 to regulate TGFβ signaling and suppress angiogenesis. Their meticulous experimental design and integrative approach have expanded the conceptual landscape of angiogenic control mechanisms, setting the stage for translational research that promises breakthroughs in managing vascular diseases. As the global burden of cancer and vascular disorders continues to rise, this discovery offers a beacon of hope, bridging molecular insight with therapeutic innovation.

This compelling study epitomizes the power of interdisciplinary research bridging cell biology, molecular signaling, and clinical relevance. The elucidation of the FRZB-Cav-1-TGFβ axis underscores the intricate mechanisms vascular cells employ to maintain homeostasis and respond dynamically to pathological stimuli. Such foundational discoveries not only inform drug development but also deepen our comprehension of vascular biology’s complexity, a prerequisite for future medical advances.

As with all groundbreaking research, questions remain regarding the broader systemic impact of manipulating this pathway and potential resistance mechanisms that pathological cells might evolve. Nevertheless, the current evidence presents a strong rationale for continued investment in this line of inquiry and highlights an exciting frontier for angiogenesis research. The prospect of leveraging endogenous regulators like FRZB to control aberrant vascular growth epitomizes a paradigm shift toward precision medicine in angiogenic diseases.

In summary, the 2026 publication by Chen CJ and team constitutes a seminal contribution to vascular biology and therapeutic science. By uncovering the FRZB-induced anti-angiogenic effect rooted in Caveolin-1-mediated TGFβ signaling, the study unlocks new opportunities for intervention in diseases driven by dysregulated angiogenesis. This knowledge not only advances scientific understanding but also offers tangible hope for innovative therapies to improve human health worldwide.

Subject of Research:
The study investigates the molecular mechanisms by which FRZB induces anti-angiogenic effects through Caveolin-1-mediated modulation of TGFβ signaling pathways.

Article Title:
FRZB-induced anti-angiogenic effect via Caveolin-1-mediated TGFβ signalling

Article References:

Chen, CJ., Zhou, L., Chen, HT. et al. FRZB-induced anti-angiogenic effect via Caveolin-1-mediated TGFβ signalling.
Nat Commun (2026). https://doi.org/10.1038/s41467-026-71326-x

Image Credits: AI Generated

Apoptosis, a meticulously regulated form of cell death, is fundamental to the preservation of cellular homeostasis. It orchestrates the systematic dismantling of damaged, infected, or excess cells, thus maintaining tissue integrity and function while preventing malignancy. Perturbations in this mechanism — notably the failure to trigger apoptotic pathways — are a hallmark of cancer, facilitating unchecked cellular proliferation and tumor progression. Current cancer therapies, including chemotherapy and radiotherapy, often aim to reactivate apoptosis by inducing cellular stress and DNA damage. Yet, a common cause of therapeutic failure is the tumor’s ability to thwart these signals, highlighting a need for deeper molecular understanding.

Central to the apoptotic machinery are proteins from the Bcl-2 family, which serve as pivotal arbiters balancing cell survival and death. Among these, Bax is a pro-apoptotic effector that, upon activation, oligomerizes to form pores within the mitochondrial outer membrane—a decisive event that commits a cell to apoptosis by releasing cytochrome c and activating downstream caspases. In contrast, Bcl-2, a well-known anti-apoptotic counterpart, acts as a guardian of mitochondrial integrity by sequestering and inhibiting Bax’s apoptotic activity. Overexpression of Bcl-2 is implicated in approximately 50% of human cancers and is strongly associated with poor clinical outcomes due to its role in fostering resistance to cell death.

The researchers employed advanced neutron scattering techniques—providing exceptional resolution and sensitivity—to dissect the interactions between Bcl-2 and Bax at the mitochondrial membrane interface. Their findings challenge earlier models which posited a simple one-to-one inhibition of Bax by Bcl-2. Instead, the study elucidates a mechanism whereby a single Bcl-2 molecule can simultaneously engage multiple Bax proteins, thereby amplifying the inhibition of apoptosis more effectively than previously appreciated. This oligomerization-driven suppression elucidates how cancerous cells can maintain survival advantages even with only modest upregulation of Bcl-2, explaining why subtle variations in Bcl-2 levels can profoundly impact tumor resilience.

The mitochondrial membrane environment itself emerged as a critical factor modulating protein interactions. The lipid composition, particularly the presence of cardiolipin—a phospholipid exclusive to mitochondrial membranes—was shown to influence Bax’s ability to oligomerize and induce pore formation. Cardiolipin fosters membrane curvature and provides a favorable scaffold for Bax activation; however, the anti-apoptotic potency of Bcl-2 remains formidable enough to counteract apoptotic signals even in cardiolipin-rich membranes. This highlights the nuanced biochemical crosstalk dictating cell fate decisions, suggesting that therapeutic strategies could target not only protein-protein interactions but also the lipid milieu of mitochondria.

Beyond providing critical mechanistic insight, these discoveries have profound therapeutic implications. By delineating the multi-faceted inhibition of Bax by Bcl-2, the study opens new paradigms for drug development aimed at dismantling cancer cell defenses. Targeting the oligomerization surfaces or the anchoring interactions of Bcl-2 could disrupt its capacity to neutralize Bax, thereby reinstating the apoptotic pathway and sensitizing tumors to existing treatments. This avenue offers substantial promise in overcoming resistance mechanisms that have long frustrated effective cancer therapy.

Lead author Gerhard Gröbner, professor at the Department of Chemistry, Umeå University, emphasizes the translational potential of these findings: “Our work provides a refined understanding of the molecular chess game played between pro- and anti-apoptotic proteins at the mitochondria. By revealing how Bcl-2 leverages oligomerization to amplify its protective role, we identify vulnerabilities that can be exploited to tip the balance back towards cell death in cancer cells.” This insight elevates the scientific community’s capacity to design precision medicines that selectively dismantle tumor survival strategies without harming healthy cells.

Collaboration was integral to this pioneering research, with contributions from notable institutions including Lund University, the European Spallation Source (ESS) in Lund, the ISIS Neutron and Muon Source and Diamond Light Source in the United Kingdom, and the Institut Laue-Langevin (ILL) in France. The interdisciplinary approach combined biophysical experiments, structural biology, and membrane biochemistry to achieve a comprehensive characterization of these apoptosis regulators at atomic and molecular scales. This synergy underscores the power of international scientific cooperation in tackling complex biomedical challenges.

The methodology harnesses the unique capabilities of neutron scattering to probe proteins embedded in lipid membranes, a formidable technical challenge given the dynamic nature and structural complexity of membrane proteins. Unlike traditional methods such as X-ray crystallography, neutron-based experiments allow researchers to capture native-like states and functional conformations of protein assemblies within lipid bilayers. This methodological advance has been pivotal in unraveling the oligomerization patterns of Bax and its inhibition by Bcl-2, setting new standards for probing membrane protein interactions in a physiologically relevant context.

Such fundamental research into mitochondria-mediated apoptosis not only elucidates cancer cell biology but also informs our understanding of numerous other diseases where apoptosis is dysregulated, including neurodegenerative disorders and autoimmune conditions. By sharpening our understanding of how cells decide life or death, this work enriches the broader biomedical landscape and inspires innovative therapeutic designs that could mitigate a spectrum of pathologies.

Looking forward, this research paves the way for the development of novel molecules designed to disrupt Bcl-2’s multifaceted binding to Bax. Pharmacological modulation of Bcl-2/Bax interactions could restore apoptosis in refractory tumor cells, thereby enhancing the efficacy of conventional cancer therapies. Furthermore, understanding how mitochondrial lipid composition modulates these protein interactions offers an additional therapeutic axis, potentially enabling combinatorial approaches that target both protein and membrane components to sensitize cancers to cell death.

In summary, the study propels the field closer to overcoming one of cancer’s most formidable defense mechanisms. By charting the molecular landscape of Bax inhibition through Bcl-2 oligomerization on mitochondrial membranes, researchers have illuminated a critical survival pathway hijacked by tumors. This knowledge sparks hope for novel, more effective treatments that can circumvent therapy resistance, ultimately improving patient outcomes and extending survival for those afflicted by stubborn malignancies. The intricate dance of proteins on mitochondrial surfaces now stands revealed as a key battlefield in the ongoing war against cancer.

Subject of Research: Cells

Article Title: Avoiding Mitochondrial Apoptosis by the Bcl-2-Driven Bax Oligomerization on Membrane Surfaces

News Publication Date: 18-Feb-2026

Web References:
http://dx.doi.org/10.1021/acschembio.5c00913

Image Credits: Photo: Mattias Pettersson, Umeå University

Keywords: Mitochondrial Apoptosis, Bcl-2, Bax, Cancer Resistance, Protein Oligomerization, Neutron Scattering, Mitochondrial Membrane, Cardiolipin, Programmed Cell Death, Cancer Therapy, Protein-Protein Interaction, Membrane Biochemistry

The investigation delves deeply into the structural and functional nuances of the KAT8-TIP60 complex, a histone acetyltransferase complex known for its critical roles in chromatin remodeling and transcriptional regulation. Until now, the upstream regulatory mechanisms controlling the integrity and activity of this complex remained incompletely understood. What Liu and colleagues have elucidated is a mechanism whereby the addition of a lactyl group at a key residue, lysine 145 of KAT8, acts as a pivotal molecular cue. This lactylation event enhances the physical interaction between KAT8 and TIP60, promoting a stable heterodimeric complex formation that significantly increases the enzymatic efficiency towards p53 acetylation.

Acetylation of p53 at lysine 120 is a well-documented determinant of p53’s pro-apoptotic activity. By modifying this specific site, the protein gains enhanced ability to activate transcription of genes involved in programmed cell death, thereby acting as a critical tumor safeguard. The novel findings presented in this study illuminate that lactylation at KAT8 lysine 145 orchestrates this acetylation event at p53 lysine 120 with remarkable coordination and precision, effectively fine-tuning the pro-apoptotic functionality of p53. This insight offers a compelling narrative that bridges metabolic cues with epigenetic regulation and apoptotic control.

Lactylation itself has recently emerged as a fascinating addition to the expanding repertoire of protein post-translational modifications. Derived from cellular metabolism, specifically from the metabolite lactate, lactylation adds a chemical group to lysine residues on proteins, influencing their interaction capabilities and functional output. The identification of lactylation at KAT8 introduces a critical metabolic-epigenetic link that may reflect how cellular metabolic states directly influence tumor suppressor pathways, revealing an elegant and sensitive mode of cellular response to stress and nutrient signals.

The authors utilized cutting-edge mass spectrometry techniques coupled with site-directed mutagenesis to pinpoint lysine 145 as the key lactylation site on KAT8. Subsequent biochemical assays provided compelling evidence that modification at this residue was both necessary and sufficient to foster KAT8-TIP60 complex assembly. Moreover, this complex demonstrated significantly higher acetyltransferase activity in vitro, particularly towards synthetic peptides mimicking the p53 acetylation site. This multilevel approach solidifies the claim that lactylation is a critical modulator of KAT8 function.

Further structural studies, employing cryo-electron microscopy, revealed that lactylation induces subtle conformational changes within the KAT8 protein that favor a more open and interaction-prone surface. This structural rearrangement would inherently facilitate the recruitment and stable binding of TIP60, which acts synergistically with KAT8 in acetyl group transfer to p53. The dynamic nature of such modifications suggests a reversible and tightly controlled regulatory axis, adding complexity but also specificity to cellular apoptotic machinery.

The biological consequences of this lactylation-driven complex formation were interrogated in cellular models of DNA damage and oncogenic stress. Cells engineered to express a lactylation-deficient mutant of KAT8 exhibited markedly diminished p53 lysine 120 acetylation and showed impaired activation of downstream apoptotic targets, leading to increased survival and proliferation. This phenotype underscores the critical importance of this modification in enabling the cell’s ability to undergo apoptosis in response to genotoxic insults, positioning lactylation as a potential ‘molecular switch’ in the decision between cell survival and death.

Notably, this discovery also unveils a poignant connection between cellular metabolism and apoptosis regulation. Lactylation is directly influenced by intracellular lactate levels, which are elevated in hypoxic tumor microenvironments and during aberrant metabolic states such as the Warburg effect commonly observed in cancer cells. By linking metabolic intermediates to the control of tumor suppressor activity, this work suggests that cancer cells may exploit or evade lactylation-mediated pathways to modulate p53 activity, opening new avenues for therapeutic intervention that target metabolic fluxes or specific post-translational modifications.

In light of these findings, targeting the enzymes responsible for lactylation or modulating the lactate pool within cells could yield innovative cancer therapies. For instance, inhibiting lactylation at KAT8 might blunt the apoptotic response, an undesirable outcome in cancer treatment; conversely, enhancing lactylation selectively could revitalize p53’s function in tumors bearing wild-type p53, overcoming one of the central hurdles in oncology. Future drug discovery efforts may focus on small molecules or peptides that specifically affect this modification or stabilize the KAT8-TIP60 interaction for maximal therapeutic benefit.

This work also raises intriguing questions about the temporal dynamics of lactylation and its interplay with other post-translational modifications, such as methylation, phosphorylation, and ubiquitination. It is conceivable that intricate crosstalk exists to finely modulate the activity and stability of KAT8, TIP60, and p53, with distinct modification patterns encoding specific cellular outcomes. Unraveling this regulatory network will require further comprehensive proteomic and biochemical investigations but promises to unveil unprecedented layers of apoptotic regulation and tumor suppression.

Beyond apoptosis, the KAT8-TIP60 complex and its regulation by lactylation may extend to other fundamental biological processes, including DNA repair, metabolism, and chromatin remodeling. Given the central roles of KAT8 and TIP60 in epigenetic control, it is plausible that lactylation integrates environmental and metabolic information into broader gene expression programs, influencing cell fate decisions far beyond apoptosis. Such broader implications highlight the transformative potential of this discovery in multiple biomedical fields.

Interestingly, the study also hints at potential diagnostic applications. Monitoring lactylation levels of KAT8 and acetylation states of p53 might serve as biomarkers for tumor progression or response to therapy, offering clinicians valuable tools to stratify patients and personalize treatments. Advances in imaging and quantification of these modifications in clinical samples could foster early detection of cancer and provide real-time insights into therapeutic efficacy.

The ramifications of this research underscore the symbiotic relationship between fundamental science and clinical innovation. Discovering how a metabolic post-translational modification governs the activation of a pivotal tumor suppressor pathway exemplifies the power of interdisciplinary approaches integrating biochemistry, structural biology, and cell biology. It opens exciting scientific horizons and benchmark standards for exploring layered regulatory mechanisms in human health and disease.

In conclusion, Liu et al.’s landmark study not only defines a new molecular mechanism by which lactylation at lysine 145 on KAT8 fosters the formation and functional potency of the KAT8-TIP60 complex but also elucidates how this metal-chemical modification stimulates p53 acetylation at lysine 120, ultimately promoting apoptosis. This revelation unites metabolic regulation with epigenetic control in a manner that could revolutionize cancer research and therapy, heralding a new era where metabolic states intricately dictate tumor suppressor activities and cell fate. The vibrant nexus of metabolism, protein modification, and transcriptional control explored herein promises to be a fertile ground for future discoveries that may unlock novel therapeutic windows for combating cancer and other diseases marked by dysregulated apoptosis.

Subject of Research: Regulation of p53 pro-apoptotic function via lactylation-driven KAT8-TIP60 complex formation

Article Title: Lactylation at lysine 145 fosters KAT8-TIP60 complex formation to promote p53 acetylation at lysine 120 and its pro-apoptotic function

Article References:
Liu, H., Li, Z., Lei, D. et al. Lactylation at lysine 145 fosters KAT8-TIP60 complex formation to promote p53 acetylation at lysine 120 and its pro-apoptotic function. Nat Commun (2026). https://doi.org/10.1038/s41467-026-71108-5

Image Credits: AI Generated